<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Several metastatic models have been developed using clonal selection of human malignant cells metastasizing into a specific organ in NIH-I Swiss immunodeficient mice </plain></SENT>
<SENT sid="1" pm="."><plain>The organs of choice were the central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>), targeted by <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> of <z:hpo ids='HP_0002861'>malignant melanoma</z:hpo>, and the liver, with <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> of <z:mp ids='MP_0009314'>colon adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Additional models of <z:e sem="disease" ids="C0854178" disease_type="Neoplastic Process" abbrv="">adrenal metastases</z:e> by <z:hpo ids='HP_0002861'>malignant melanoma</z:hpo>, and <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement by implanted human lung squamous <z:mp ids='MP_0002038'>carcinoma</z:mp> or lymphoblastoid cells, are also available </plain></SENT>
<SENT sid="3" pm="."><plain>Organ <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>, as well as the effects of treatment, were confirmed by autopsies and histological examination of the tissues or by a surgical inspection of the liver </plain></SENT>
<SENT sid="4" pm="."><plain>The treatment end points were established as the increases in survival times of treated mice relative to placebo-treated controls </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="27656">Camptothecins</z:chebi> injected i.m. or delivered via gastrointestinal tract inhibit the growth of <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> and increase the survival of treated animals </plain></SENT>
<SENT sid="6" pm="."><plain>9-Amino-20(S)-<z:chebi fb="0" ids="27656">camptothecin</z:chebi> was effective in the <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> model and in the model of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The drug increased 3.3- and 5.7-fold the survival rates relative to untreated controls with <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> of <z:mp ids='MP_0009314'>colon adenocarcinoma</z:mp> to the liver, and <z:hpo ids='HP_0000001'>all</z:hpo> <z:chebi fb="0" ids="27656">camptothecins</z:chebi> were significantly more effective than <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi>, currently a drug of choice in treatment of this disease </plain></SENT>
<SENT sid="8" pm="."><plain>The <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> are available for studies of drug passage through the blood-brain barrier optimization of drug delivery to the liver, and for the development of new <z:chebi fb="0" ids="27656">camptothecin</z:chebi>-based treatment strategies </plain></SENT>
</text></document>